The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): a randomised, double-blind, placebo-controlled trial

[1]  C. Mulert,et al.  Resolving and Rescuing Developmental Miswiring in a Mouse Model of Cognitive Impairment , 2019, Neuron.

[2]  S. Reeves,et al.  Minocycline at 2 Different Dosages vs Placebo for Patients With Mild Alzheimer Disease , 2019, JAMA neurology.

[3]  Jennifer M. Coughlin,et al.  PET studies of the glial cell marker TSPO in psychosis patients - a meta-analysis using individual participant data , 2017, bioRxiv.

[4]  Alan A. Wilson,et al.  Association of translocator protein total distribution volume with duration of untreated major depressive disorder: a cross-sectional study. , 2018, The lancet. Psychiatry.

[5]  W. Drevets,et al.  Treatment of bipolar depression with minocycline and/or aspirin: an adaptive, 2×2 double-blind, randomized, placebo-controlled, phase IIA clinical trial , 2018, Translational Psychiatry.

[6]  Sophie E. Holmes,et al.  Elevated Translocator Protein in Anterior Cingulate in Major Depression and a Role for Inflammation in Suicidal Thinking: A Positron Emission Tomography Study , 2018, Biological Psychiatry.

[7]  A. Young,et al.  Minocycline as an adjunct for treatment-resistant depressive symptoms: A pilot randomised placebo-controlled trial , 2017, Journal of psychopharmacology.

[8]  A. Traboulsee,et al.  Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis , 2017, The New England journal of medicine.

[9]  J. Bobes,et al.  The course of negative symptoms in first-episode schizophrenia and its predictors: A prospective two-year follow-up study , 2017, Schizophrenia Research.

[10]  D. Kelly,et al.  Adjunctive minocycline for schizophrenia: A meta-analysis of randomized controlled trials , 2017, European Neuropsychopharmacology.

[11]  T. Möller,et al.  Critical data‐based re‐evaluation of minocycline as a putative specific microglia inhibitor , 2016, Glia.

[12]  R. Murray,et al.  Cortisol and Inflammatory Biomarkers Predict Poor Treatment Response in First Episode Psychosis , 2015, Schizophrenia bulletin.

[13]  Peter B. Jones,et al.  The benefit of minocycline on negative symptoms in early-phase psychosis in addition to standard care - extent and mechanism (BeneMin): study protocol for a randomised controlled trial , 2015, Trials.

[14]  N. Barnes,et al.  Cytokine function in medication-naive first episode psychosis: A systematic review and meta-analysis , 2014, Schizophrenia Research.

[15]  Jingping Zhao,et al.  Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: A double blind, randomized, controlled trial , 2014, Schizophrenia Research.

[16]  Lu Liu,et al.  Reliability and validity of the Calgary Depression Scale for Schizophrenia (CDSS) in youth at clinical high risk for psychosis , 2014, Schizophrenia Research.

[17]  J. P. McCoy,et al.  Baseline Levels and Temporal Stability of 27 Multiplexed Serum Cytokine Concentrations in Healthy Subjects , 2013, PloS one.

[18]  G. Dunn,et al.  Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment , 2012, Journal of psychopharmacology.

[19]  John Suckling,et al.  The neuro/PsyGRID calibration experiment , 2012, Human brain mapping.

[20]  Guy B. Williams,et al.  MRI detection of tissue pathology beyond atrophy in Alzheimer's disease: Introducing T2-VBM , 2011, NeuroImage.

[21]  M. Cudkowicz.  A futility study of minocycline in Huntington's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[22]  Y. Levkovitz,et al.  A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. , 2010, The Journal of clinical psychiatry.

[23]  Alexander Gerhard,et al.  Minocycline 1‐year therapy in multiple‐system‐atrophy: Effect on clinical symptoms and [11C] (R)‐PK11195 PET (MEMSA‐trial) , 2010, Movement disorders : official journal of the Movement Disorder Society.

[24]  M. Minzenberg,et al.  Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia. , 2009, Archives of general psychiatry.

[25]  R. Kahn,et al.  Psychosis and brain volume changes during the first five years of schizophrenia , 2009, European Neuropsychopharmacology.

[26]  R. Boellaard,et al.  Microglia Activation in Recent-Onset Schizophrenia: A Quantitative (R)-[11C]PK11195 Positron Emission Tomography Study , 2008, Biological Psychiatry.

[27]  H. Yasuda,et al.  Minocycline as Adjunctive Therapy for Schizophrenia: An Open-Label Study , 2008, Clinical neuropharmacology.

[28]  Ninds Net-Pd Investigators.  A Pilot Clinical Trial of Creatine and Minocycline in Early Parkinson Disease: 18-Month Results , 2008, Clinical neuropharmacology.

[29]  H. Mitsumoto,et al.  Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial , 2007, The Lancet Neurology.

[30]  M. Boaz,et al.  Minocycline treatment in acute stroke , 2007, Neurology.

[31]  Timothy Edward John Behrens,et al.  Anatomically related grey and white matter abnormalities in adolescent-onset schizophrenia. , 2007, Brain : a journal of neurology.

[32]  John D. Ainsworth,et al.  The PsyGrid Experience: Using Web Services in the Study of Schizophrenia , 2007, Int. J. Heal. Inf. Syst. Informatics.

[33]  Stefan Leucht,et al.  What does the PANSS mean? , 2005, Schizophrenia Research.

[34]  D. Glahn,et al.  Beyond hypofrontality: A quantitative meta‐analysis of functional neuroimaging studies of working memory in schizophrenia , 2005, Human brain mapping.

[35]  John Suckling,et al.  Different Effects of Typical and Atypical Antipsychotics on Grey Matter in First Episode Psychosis: the ÆSOP Study , 2005, Neuropsychopharmacology.

[36]  J. Lieberman,et al.  Antipsychotic drug effects on brain morphology in first-episode psychosis. , 2005, Archives of general psychiatry.

[37]  Carlos Matute,et al.  Neuroprotection by tetracyclines. , 2004, Trends in pharmacological sciences.

[38]  John Suckling,et al.  For personal use. Only reproduce with permission from The Lancet Publishing Group. Effect of sunlight and season on serotonin turnover in the brain , 2002 .

[39]  N. Tzourio-Mazoyer,et al.  Automated Anatomical Labeling of Activations in SPM Using a Macroscopic Anatomical Parcellation of the MNI MRI Single-Subject Brain , 2002, NeuroImage.

[40]  J. Gold,et al.  Short form of the WAIS-III for use with patients with schizophrenia , 2000, Schizophrenia Research.

[41]  D. Sheehan,et al.  The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. , 1998, The Journal of clinical psychiatry.

[42]  F. Breedveld,et al.  Inflammatory and immunological parameters of disease activity in rheumatoid arthritis patients treated with minocycline. , 1996, Immunopharmacology.

[43]  P. Crichton,et al.  Verbal fluency in schizophrenia: relationship with executive function, semantic memory and clinical alogia , 1996, Psychological Medicine.

[44]  M. Birchwood,et al.  programmes with schizophrenic patients. new scale of social adjustment for use in family intervention The Social Functioning Scale. The development and validation of a , 2022 .

[45]  H. Olders,et al.  Negative Symptoms in Schizophrenia , 1990, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[46]  S. Kay,et al.  The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.

[47]  T. Crow,et al.  The two-syndrome concept: origins and current status. , 1985, Schizophrenia bulletin.

[48]  N C Andreasen,et al.  Negative symptoms in schizophrenia , 1982 .